Visium Asset Management’s TG Therapeutics TGTX Stock Holding History

Visium Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-525,000	Closed	-$4.47M	–	480
2016 Q1	$4.47M	Buy	+525,000	New	+$4.59M	0.08%	278
2015 Q4	–	Sell	-500,000	Closed	-$5.04M	–	846
2015 Q3	$5.04M	Sell	500,000 -30,000	-6%	-$447K	0.07%	296
2015 Q2	$8.79M	Sell	530,000 -771,500	-59%	-$12.2M	0.12%	176
2015 Q1	$20.1M	Buy	1,301,500 +101,500	+8%	+$1.54M	0.3%	70
2014 Q4	$19M	Buy	1,200,000 +359,454	+43%	+$4.68M	0.27%	70
2014 Q3	$8.97M	Buy	840,546 +210,166	+33%	+$1.95M	0.13%	159
2014 Q2	$5.92M	Buy	+630,380	New	+$4.03M	0.09%	203

Other funds holding TGTX

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Visium Asset Management's TGTX Position: Q2 2016 in Review

Visium Asset Management sold out of TG Therapeutics (TGTX) in Q2 2016, closing a stake of 525,000 shares — an estimated $4.47M sold.

Visium Asset Management first reported a position in TGTX in Q2 2014 and held it in 7 quarters. The position peaked at $20.1M in Q1 2015. 91 funds tracked by Wall St. Rank hold TGTX as of Q2 2016.

Visium Asset Management reported no remaining TG Therapeutics position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 525,000 TG Therapeutics shares in Q2 2016, an estimated $4.47M.
Visium Asset Management first reported a position in TG Therapeutics in Q2 2014 and held it in 7 quarters.
Visium Asset Management's TG Therapeutics position peaked at $20.1M in Q1 2015.
91 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.